TABLE 3.

Grade 3 Hematologic Adverse Events After Start of ²²³Ra Therapy*

	Incidence (n = 26)
Patients with events†	Overall	Starting before 177Lu-PSMA treatment	Starting during or after 177Lu-PSMA treatment‡
Any	9 (35%)	5 (19%)	5 (19%)
Leukopenia	0	0	0
Neutropenia	0	0	0
Pancytopenia	1 (4%)	0	1 (4%)
Thrombocytopenia	3 (12%)	2 (8%)	1 (4%)
Anemia	6 (23%)	3 (12%)	4 (15%)

*No grade ≥4 events were recorded.

^†Patients may have had >1 event at different times; these patients are counted only once in “Any” row and “Overall” column.

^‡Grade 3/4 hematologic toxicity data were systematically recorded only up to 6 mo after completion of ²²³Ra therapy; data are therefore not consistently available for patients who received ¹⁷⁷Lu-PSMA after this window.

Qualitative data are number and percentage.